Tumor Targeted Nanobubbles for Real-Time Ultrasound-Guided Prostate Cancer Biopsy and Therapy

**PSMA-Nanobubbles (PSMA-NB) bind to cancer cells for ultrasonic diagnosis and guided biopsy of prostate tumors. Ultrasonic excitation of PSMA-NB, known as TNT, kills cancer cells and expands technology to therapeutic applications.**

**Technology**
- Prostate tumors are difficult to detect and biopsies are done blindly
- PSMA-labeled Nanobubbles given before biopsy with single IV shot, home to and bind specifically to prostate tumors
- PSMA-Nanobubbles serve as beacons to visualize the tumors; creating ultrasonic tumor maps to guide the urologist during biopsies to the tumor site
- Procedure fits into existing workflow, builds upon existing technology
- Platform technology with therapeutic potential known as Targeted Nanobubble Therapy or “TNT” – sends an ultrasonic pulse to the bound PSMA-Nanobubbles killing the tumor cells in a precise cancer therapy approach

**Opportunity**
- Nearly 1.3 million prostate biopsies / year in USA
- Estimated cost of a nanobubble injection: $300-$500
- Total US market opportunity: $390M for initial biopsy plus $63M for follow up biopsies
- Healthcare cost savings: reduction in repeat biopsies can reduce costs by >$2.3B
- PSMA also expressed in head and neck cancers, some lung cancers, and the neovasculature of many solid tumors
- Therapeutic opportunity is even larger

**Seeking**
- Licensing of IP
- Start-up Leadership
- Investment to develop and commercialize the technology
- Sponsored research

**Technology Readiness**
- Large animal studies underway, non-GMP Tox completed; Clinical studies planned

**Commercial Pathway**
- Available for licensing and/or start-up consideration

**Intellectual Property**
- 1 issued patent, 5 pending applications

Inventors: Agata Exner, Ph.D.; Jim Basilion, Ph.D.
Licensing Contact: Stacy Fening, Ph.D. | (216) 368-0451 | stacy.fening@case.edu